ITOS - iTeos Pharma Total Debt to Capital

iTeos Therapeutics (ITOS) focuses on developing targeted oncology treatments by activating the body's own immune defenses. This chart for the stock on the GURU.Markets platform shows the total debt-to-equity metric as 0.01. Operations in the US and Belgium rely on partner support and successful trial outcomes, while the company strictly adheres to laboratory waste disposal protocols to minimize environmental impact.

Conservative capital requires transparency in financing structures to assess business resilience to rate volatility. This indicator measures the proportion of borrowed funds relative to equity, determining the level of financial risk and dependence on external creditors. For the biotech firm iTeos Therapeutics (ITOS), which invests in R&D and scientist retention through stock options, the company's debt leverage history demonstrates a balance between equity and debt obligations.